txa (Daiichi Sankyo)
86
Structured Review
Daiichi Sankyo
txa
Txa, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/pmc12897568-100-8-9
Average 86 stars, based on 1 article reviews
Txa, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/txa/txa/pmc12897568-100-8-9
Average 86 stars, based on 1 article reviews
txa - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Saline:Article Title: Efficacy of intravenous tranexamic acid administration in medial opening-wedge distal tibial tuberosity osteotomy (MOWDTO) for varus knee osteoarthritis: a randomized control trial. Article Snippet: .. In the Injection:Article Title: The Efficacy of Intra-articular Tranexamic Acid Injection With Different Drainage Clamping Time in Postoperative Bleeding and Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction Article Snippet: .. Additionally, in the TXA group, 10 mL of Article Title: Effects of intra-articular tranexamic acid injection with different acting times after anterior cruciate ligament reconstruction: a cohort study with historical controls. Article Snippet: .. A total of 10 mL of Article Title: Intra-articular Injection of Tranexamic Acid Reduced Postoperative Hemarthrosis in Arthroscopic Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Study. Article Snippet: Purpose: To evaluate the effect of intra-articular injection of tranexamic acid (TXA) in patients receiving arthroscopic anterior cruciate ligament reconstruction (ACLR).. Methods: A total of 304 patients were included in this study, which was performed between August 2017 and April 2018.. Single-bundle reconstructions using autologous hamstring tendon grafts were performed in all patients. Control:Article Title: Tranexamic Acid for Acute Upper Respiratory Tract Infection‐Associated Sore Throat Pain: A Randomized Controlled Trial Article Snippet: .. They either received 1 g preparation of 50% Article Title: Antifibrinolytics for heavy menstrual bleeding Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; Software:Article Title: Antifibrinolytics for heavy menstrual bleeding Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; Sequencing:Article Title: Antifibrinolytics for heavy menstrual bleeding Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; Selection:Article Title: Antifibrinolytics for heavy menstrual bleeding Article Snippet: Published by John Wiley & Sons, Ltd. Preston 1995 (Continued) Exclusion criteria: abnormal renal function; abnormal pelvic examination; abnormal cervical smear; anovulatory cycles; lack of compliance during the placebo cycles Interventions 2 months of placebo (to assess eligibility) followed by 2 months of either TXA (25 participants) 1 g taken 4 times daily on days 1 to 4 or NET (21 participants) 5 mg taken twice daily on days 19 to 26 of cycle Outcomes Objective MBL: measured via the alkaline haematin method (end scores) QoL assessed using a questionnaire (at end of cycle 2 and cycle 4) using 5-point scale for general health, amount of flooding and leakage experienced, abdominal pain, limitation to social life, effect on sex life Diary of days bleeding, number of sanitary towels used and side effects recorded by participants Notes Originally 103 women were recruited but 57 were excluded during the placebo cycles because of lack of objective menorrhagia (> 80 mL per cycle), anovulation or lack of compliance with protocol Additional data were provided by the author Funded by Pharmacia (a drug company) Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk “Randomization was by computer generated numbers” Allocation concealment (selection bias) Low risk Adequate: “opaque sealed, consecutively numbered envelopes” Blinding (performance bias and detection bias) All outcomes Low risk Authors stated that the other group took “placebo of identical appearance to the active drug” and the treatment regimen was also the same for each group Incomplete outcome data (attrition bias) All outcomes Low risk 4 women did not complete the trial, but all were included in the results Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported Other bias Low risk Groups appeared comparable at baseline 50Antifibrinolytics for heavy menstrual bleeding (Review) Copyright © 2018 The Cochrane Collaboration. .. Published by John Wiley & Sons, Ltd. Zhang 2008 Methods Multi-centre, open label RCT: method of randomization used computer software Blinding was highly unlikely, given the differences in the treatment regimens (1 group took tablets twice a day, the other 3 times a day) Given treatment for 2 cycles, then followed-up for 1 further cycle Participants Country: China Age: mean age 35 years old Number of participants: 106 women Inclusion criteria: “proven ovulatory menorrhagia”, attending gynaecological clinics, PBAC score > 130 Exclusion criteria: heart, kidney, liver or haematological disease; having had any hormonal treatments in the 3 months prior, including an IUS; |
